|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
Advertisement
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Accelerate Inclusive Enrollment and Delivery with LightshipFebruary 19th 2025
Harmonizing Data in Clinical ResearchOctober 21st 2024
Parexel’s FSP: Evolving With Your Needs Now and in the FutureOctober 3rd 2024
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
